,Consolidated Statements of Cash Flows - USD ($) $ in Millions,12 Months Ended,12 Months Ended,12 Months Ended
,Consolidated Statements of Cash Flows - USD ($) $ in Millions.1,"Dec. 31, 2018","Dec. 31, 2017","Dec. 31, 2016"
"('Consolidated Statements of Cash Flows - USD ($) $ in Millions', 'Consolidated Statements of Cash Flows - USD ($) $ in Millions')",,,,
Operating Activities,,,,
Net income before allocation to noncontrolling interests,[1][2][3][4], 11188, 21355, 7246
Adjustments to reconcile net income before allocation to noncontrolling interests to net cash provided by operating activities:,,,,
Depreciation and amortization,[1],6384,6269,5757
Asset write-offs and impairments,[1],3398,634,1613
Loss on sale of HIS net assets,[1][5],-1,55,1712
TCJA impact,[1][6],-596,-10660,0
Deferred taxes from continuing operations,[1],-2205,-2410,-700
Share-based compensation expense,[1],949,840,691
Benefit plan contributions in excess of expense,[1],-1095,-961,-712
"Other adjustments, net",[1],-1268,344,487
"Other changes in assets and liabilities, net of acquisitions and divestitures:",,,,
Trade accounts receivable,[1],-644,259,-134
Inventories,[1],-717,-357,365
Other assets,[1],-16,7,-47
Trade accounts payable,[1],431,46,871
Other liabilities,[1],98,-67,-223
"Other tax accounts, net",[1],-78,1446,-734
Net cash provided by operating activities,[1],15827,16802,16192
Investing Activities,,,,
"Purchases of property, plant and equipment",[1],-2042,-1956,-1823
Purchases of short-term investments,[1],-11677,-14596,-15957
Proceeds from redemptions/sales of short-term investments,[1],17581,10302,29414
Net (purchases of)/proceeds from redemptions/sales of short-term investments with original maturities of three months or less,[1],-3917,2058,-4218
Purchases of long-term investments,[1],-1797,-3537,-8011
Proceeds from redemptions/sales of long-term investments,[1],6244,3579,11268
"Acquisitions of businesses, net of cash acquired",[1],0,-1000,-18368
Acquisitions of intangible assets,[1],-154,-261,-176
"Other investing activities, net",[1][7],288,671,80
Net cash provided by/(used in) investing activities,[1],4525,-4740,-7791
Financing Activities,,,,
Proceeds from short-term borrowings,[1],3711,8464,7472
Principal payments on short-term borrowings,[1],-4437,-9947,-5093
Net (payments on)/proceeds from short-term borrowings with original maturities of three months or less,[1],-1617,1422,-3060
Proceeds from issuance of long-term debt,[1],4974,5274,10976
Principal payments on long-term debt,[1],-3566,-6154,-7689
Purchases of common stock,[1],-12198,-5000,-5000
Cash dividends paid,[1],-7978,-7659,-7317
Proceeds from exercise of stock options,[1],1259,862,1019
"Other financing activities, net",[1],-588,-611,-536
Net cash used in financing activities,[1],-20441,-13350,-9228
Effect of exchange-rate changes on cash and cash equivalents and restricted cash and cash equivalents,[1],-116,53,-215
Net decrease in cash and cash equivalents and restricted cash and cash equivalents,[1],-205,-1235,-1041
"Cash and cash equivalents and restricted cash and cash equivalents, beginning",[1],1431,2666,3707
"Cash and cash equivalents and restricted cash and cash equivalents, end",[1],1225,1431,2666
Supplemental Cash Flow Information,,,,
"Exchange of $1.1 billion net book value 6.50% U.K. pound denominated bonds maturing in 2038 for $1.8 billion of new 2.735% U.K. pound denominated bonds maturing in 2043, resulting in a debt extinguishment loss of $747 million",[1][8],0,1848,0
Receipt of ICU Medical common stock,[1][7],0,428,0
Promissory note from ICU Medical,[1][7],0,75,0
Cash paid (received) during the period for:,,,,
Income taxes,[1],3655,2489,2521
Interest,[1],1311,1518,1451
Interest rate hedges,[1],-38,-199,-338
Cerevel Therapeutics [Member],,,,
Supplemental Cash Flow Information,,,,
Equity investment in exchange for Pfizer's assets,[1][7],343,0,0
Allogene [Member],,,,
Supplemental Cash Flow Information,,,,
Equity investment in exchange for Pfizer's assets,[1][7], 92, 0, 0
,,,,
"[1] Amounts may not add due to rounding. [2] Amounts may not add due to rounding. [3] Amounts may not add due to rounding. [4] Amounts may not add due to rounding. [5] In 2018 and 2017, represents adjustments to amounts previously recorded in 2016 to write down the HIS net assets to fair value less costs to sell related to the sale of HIS net assets to ICU Medical on February 3, 2017. In 2016, represents a charge related to the write-down of the HIS net assets to fair value less estimated costs to sell. See Note 2B for additional information. [6] As a result of the enactment of the TCJA in December 2017, Pfizer’s Provision/(benefit) for taxes on income (i) for the year ended December 31, 2017 was favorably impacted by approximately $10.7 billion, primarily reflecting the remeasurement of U.S. deferred tax liabilities, which includes the repatriation tax on deemed repatriated accumulated post-1986 earnings of foreign subsidiaries and (ii) for the year ended December 31, 2018 was favorably impacted by approximately $600 million, primarily related to certain tax initiatives associated with the TCJA, as well as favorable adjustments to the provisional estimates of the legislation. See Note 5A. Tax Matters: Taxes on Income from Continuing Operations for additional information. [7] For additional information, see Note 2B. Acquisitions, Divestitures, Assets and Liabilities Held for Sale, Licensing Arrangements, Research and Development and Collaborative Arrangements, Equity-Method Investments and Privately Held Investment: Divestitures. [8] The $747 million is included in the net loss of $846 million upon the exchange and early retirement of the U.K. pound-denominated debt. See Note 7D. Financial Instruments: Long-Term Debt for additional information.",[1] Amounts may not add due to rounding. [2] Amounts may not add due to rounding. [3] Amounts may not add due to rounding. [4] Amounts may not add due to rounding. [5] In 2018 and 2017 represents adjustments to amounts previously recorded in 2016 to write down the HIS net assets to fair value less costs to sell related to the sale of HIS net assets to ICU Medical on February 3 2017. In 2016 represents a charge related to the write-down of the HIS net assets to fair value less estimated costs to sell. See Note 2B for additional information. [6] As a result of the enactment of the TCJA in December 2017 Pfizer’s Provision/-benefit for taxes on income -i for the year ended December 31 2017 was favorably impacted by approximately 10.7 billion primarily reflecting the remeasurement of U.S. deferred tax liabilities which includes the repatriation tax on deemed repatriated accumulated post-1986 earnings of foreign subsidiaries and -ii for the year ended December 31 2018 was favorably impacted by approximately 600 million primarily related to certain tax initiatives associated with the TCJA as well as favorable adjustments to the provisional estimates of the legislation. See Note 5A. Tax Matters: Taxes on Income from Continuing Operations for additional information. [7] For additional information see Note 2B. Acquisitions Divestitures Assets and Liabilities Held for Sale Licensing Arrangements Research and Development and Collaborative Arrangements Equity-Method Investments and Privately Held Investment: Divestitures. [8] The 747 million is included in the net loss of 846 million upon the exchange and early retirement of the U.K. pound-denominated debt. See Note 7D. Financial Instruments: Long-Term Debt for additional information.,[1] Amounts may not add due to rounding. [2] Amounts may not add due to rounding. [3] Amounts may not add due to rounding. [4] Amounts may not add due to rounding. [5] In 2018 and 2017 represents adjustments to amounts previously recorded in 2016 to write down the HIS net assets to fair value less costs to sell related to the sale of HIS net assets to ICU Medical on February 3 2017. In 2016 represents a charge related to the write-down of the HIS net assets to fair value less estimated costs to sell. See Note 2B for additional information. [6] As a result of the enactment of the TCJA in December 2017 Pfizer’s Provision/-benefit for taxes on income -i for the year ended December 31 2017 was favorably impacted by approximately 10.7 billion primarily reflecting the remeasurement of U.S. deferred tax liabilities which includes the repatriation tax on deemed repatriated accumulated post-1986 earnings of foreign subsidiaries and -ii for the year ended December 31 2018 was favorably impacted by approximately 600 million primarily related to certain tax initiatives associated with the TCJA as well as favorable adjustments to the provisional estimates of the legislation. See Note 5A. Tax Matters: Taxes on Income from Continuing Operations for additional information. [7] For additional information see Note 2B. Acquisitions Divestitures Assets and Liabilities Held for Sale Licensing Arrangements Research and Development and Collaborative Arrangements Equity-Method Investments and Privately Held Investment: Divestitures. [8] The 747 million is included in the net loss of 846 million upon the exchange and early retirement of the U.K. pound-denominated debt. See Note 7D. Financial Instruments: Long-Term Debt for additional information.,[1] Amounts may not add due to rounding. [2] Amounts may not add due to rounding. [3] Amounts may not add due to rounding. [4] Amounts may not add due to rounding. [5] In 2018 and 2017 represents adjustments to amounts previously recorded in 2016 to write down the HIS net assets to fair value less costs to sell related to the sale of HIS net assets to ICU Medical on February 3 2017. In 2016 represents a charge related to the write-down of the HIS net assets to fair value less estimated costs to sell. See Note 2B for additional information. [6] As a result of the enactment of the TCJA in December 2017 Pfizer’s Provision/-benefit for taxes on income -i for the year ended December 31 2017 was favorably impacted by approximately 10.7 billion primarily reflecting the remeasurement of U.S. deferred tax liabilities which includes the repatriation tax on deemed repatriated accumulated post-1986 earnings of foreign subsidiaries and -ii for the year ended December 31 2018 was favorably impacted by approximately 600 million primarily related to certain tax initiatives associated with the TCJA as well as favorable adjustments to the provisional estimates of the legislation. See Note 5A. Tax Matters: Taxes on Income from Continuing Operations for additional information. [7] For additional information see Note 2B. Acquisitions Divestitures Assets and Liabilities Held for Sale Licensing Arrangements Research and Development and Collaborative Arrangements Equity-Method Investments and Privately Held Investment: Divestitures. [8] The 747 million is included in the net loss of 846 million upon the exchange and early retirement of the U.K. pound-denominated debt. See Note 7D. Financial Instruments: Long-Term Debt for additional information.,[1] Amounts may not add due to rounding. [2] Amounts may not add due to rounding. [3] Amounts may not add due to rounding. [4] Amounts may not add due to rounding. [5] In 2018 and 2017 represents adjustments to amounts previously recorded in 2016 to write down the HIS net assets to fair value less costs to sell related to the sale of HIS net assets to ICU Medical on February 3 2017. In 2016 represents a charge related to the write-down of the HIS net assets to fair value less estimated costs to sell. See Note 2B for additional information. [6] As a result of the enactment of the TCJA in December 2017 Pfizer’s Provision/-benefit for taxes on income -i for the year ended December 31 2017 was favorably impacted by approximately 10.7 billion primarily reflecting the remeasurement of U.S. deferred tax liabilities which includes the repatriation tax on deemed repatriated accumulated post-1986 earnings of foreign subsidiaries and -ii for the year ended December 31 2018 was favorably impacted by approximately 600 million primarily related to certain tax initiatives associated with the TCJA as well as favorable adjustments to the provisional estimates of the legislation. See Note 5A. Tax Matters: Taxes on Income from Continuing Operations for additional information. [7] For additional information see Note 2B. Acquisitions Divestitures Assets and Liabilities Held for Sale Licensing Arrangements Research and Development and Collaborative Arrangements Equity-Method Investments and Privately Held Investment: Divestitures. [8] The 747 million is included in the net loss of 846 million upon the exchange and early retirement of the U.K. pound-denominated debt. See Note 7D. Financial Instruments: Long-Term Debt for additional information.
